Core Viewpoint - Yunnan Watson Bio-Technology Co., Ltd. has signed an amendment to the exclusive sublicense agreement with Notitia Biotechnologies Company to expand its development and commercialization rights in the field of gut microbiota health targeting non-patient populations, aligning with national health strategies [1][2]. Group 1: Agreement Details - The amendment allows Watson Bio to exclusively develop, manufacture, and commercialize core microbiota analysis, targeted transplantation, and nutritional formula technologies in mainland China, Hong Kong, and Macau for non-patient populations [1][2]. - The agreement aims to establish a dual-track layout of "disease treatment intervention" and "chronic disease prevention + health nutrition," providing comprehensive health solutions [1][2]. - The amendment does not constitute a related party transaction or a major asset restructuring as defined by regulations [1][2]. Group 2: Financial Terms - Watson Bio will pay Notitia a total of $1,500,000 in license issue fees, with specific payment schedules outlined [3][4]. - Ongoing royalties will be 6.5% of net sales from sublicensed products, with minimum royalty payments established for subsequent years [4][5]. - Milestone payments are structured based on the achievement of specific regulatory approvals and sales targets, with amounts ranging from $500,000 to $30,500,000 [5][6]. Group 3: Company Impact - The signing of the amendment is not expected to significantly impact the company's operating performance for the current year, as the financial arrangements are closely tied to product development progress [6]. - The payment structure is designed to ensure efficient use of funds and alleviate short-term financial burdens on the company [6].

Core Viewpoint - Watson Bio has signed an exclusive sublicensing agreement with Notitia Biotechnologies to expand its collaboration into the non-patient field, allowing for the development and commercialization of specific technologies in China, Hong Kong, and Macau [1] Group 1: Agreement Details - The exclusive sublicensing agreement was signed on May 23, 2025, focusing on the "patient field" initially [1] - The amendment to the agreement aims to include relevant intellectual property and proprietary technology for the non-patient field [1] Group 2: Technology and Rights - Notitia will grant Watson Bio exclusive rights to develop, manufacture, and commercialize core microbiome analysis, microbiome-targeted transplantation, and nutritional formulation technologies in mainland China, Hong Kong, and Macau [1] - These technologies are derived from an upstream licensing agreement between Notitia and Rutgers University in New Jersey [1]